NO20022558L - 4-karboksyamino-2-etyl-1,2,3,4-tetrahydrokinolinkrystall som CETP inhibitor - Google Patents

4-karboksyamino-2-etyl-1,2,3,4-tetrahydrokinolinkrystall som CETP inhibitor

Info

Publication number
NO20022558L
NO20022558L NO20022558A NO20022558A NO20022558L NO 20022558 L NO20022558 L NO 20022558L NO 20022558 A NO20022558 A NO 20022558A NO 20022558 A NO20022558 A NO 20022558A NO 20022558 L NO20022558 L NO 20022558L
Authority
NO
Norway
Prior art keywords
carboxyamino
tetrahydroquinoline
ethyl
crystal
cetp inhibitor
Prior art date
Application number
NO20022558A
Other languages
English (en)
Other versions
NO20022558D0 (no
Inventor
Douglas John Meldrum Allen
Troy Anthony Appleton
Lyle Ribinson Brostrom
Derek Lawrence Tickner
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20022558D0 publication Critical patent/NO20022558D0/no
Publication of NO20022558L publication Critical patent/NO20022558L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Det er beskrevet krystallinske former av en CETP inhibitor med formel (I), fremgangsmåte for fremstilling av krystaller, fremgangsmåte for anvendelse av krystallene, og farmasøytiske preparater inneholdende krystallene er også beskrevet.
NO20022558A 1999-11-30 2002-05-29 4-karboksyamino-2-etyl-1,2,3,4-tetrahydrokinolinkrystall som CETP inhibitor NO20022558L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16805199P 1999-11-30 1999-11-30
PCT/IB2000/001650 WO2001040190A1 (en) 1999-11-30 2000-11-14 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor

Publications (2)

Publication Number Publication Date
NO20022558D0 NO20022558D0 (no) 2002-05-29
NO20022558L true NO20022558L (no) 2002-05-29

Family

ID=22609901

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022558A NO20022558L (no) 1999-11-30 2002-05-29 4-karboksyamino-2-etyl-1,2,3,4-tetrahydrokinolinkrystall som CETP inhibitor

Country Status (28)

Country Link
EP (1) EP1246804A1 (no)
JP (1) JP2003515592A (no)
KR (1) KR20020058057A (no)
CN (1) CN1402711A (no)
AP (1) AP2002002531A0 (no)
AU (1) AU1048801A (no)
BG (1) BG106854A (no)
BR (1) BR0015836A (no)
CA (1) CA2392979A1 (no)
CO (1) CO5271716A1 (no)
EA (1) EA200200510A1 (no)
EC (1) ECSP003792A (no)
EE (1) EE200200277A (no)
GT (1) GT200000199A (no)
HU (1) HUP0203521A2 (no)
IL (1) IL149097A0 (no)
IS (1) IS6338A (no)
MA (1) MA26845A1 (no)
MX (1) MXPA02005354A (no)
NO (1) NO20022558L (no)
OA (1) OA12099A (no)
PA (1) PA8506301A1 (no)
PE (1) PE20010904A1 (no)
PL (1) PL355892A1 (no)
TN (1) TNSN00231A1 (no)
TR (1) TR200201446T2 (no)
UY (1) UY26454A1 (no)
WO (1) WO2001040190A1 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
HUP0400263A2 (hu) * 2001-06-21 2005-03-29 Pfizer Products Inc. Koleszteril-észter transzfer protein inhibitort tartalmazó önemulgeáló készítmény
GT200200170A (es) 2001-09-28 2003-05-23 Preparacion de inhibidor de cetp anhidro
MXPA04007433A (es) * 2002-02-01 2004-10-11 Pfizer Prod Inc Procedimiento para preparar dispersiones solidas amorfas homogeneas de farmaco secadas por pulverizacion utilizando un dispositivo de secado por pulverizacion modificado.
EP1920766B1 (en) * 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
JP2005523262A (ja) 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
ES2277142T3 (es) 2002-08-30 2007-07-01 Japan Tobacco Inc. Compuesto de dibencilamina y su uso medicinal.
MXPA05003456A (es) 2002-10-04 2005-07-05 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
ATE407670T1 (de) 2002-12-20 2008-09-15 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
CA2519458A1 (en) 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
BRPI0408897A (pt) * 2003-03-28 2006-04-18 Pfizer Prod Inc derivados de 1,2,3,4-tetrahidro-e 1,2-dihidro-quinolina 1,2,4-substituìdos como inibidores de cetp para o tratamento de arteroesclerose e obesidade
ATE540671T1 (de) 2003-08-04 2012-01-15 Bend Res Inc Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien
BRPI0414186A (pt) 2003-10-08 2006-10-31 Lilly Co Eli compostos, métodos de antagonizar a atividade de cetp, de tratar ou prevenir uma doença, de diminuir o colesterol ldl plasmático em um mamìmero, de tratar e/ou prevenir seqüelas patológicas, formulação farmacêutica, e, uso de um composto
AU2005233160B2 (en) * 2004-04-13 2011-06-02 Merck Sharp & Dohme Corp. CETP inhibitors
CA2570688A1 (en) * 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2006033004A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds as cetp inhibitors
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
AU2006216713A1 (en) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
AR065670A1 (es) 2007-03-09 2009-06-24 Indigene Pharmaceuticals Inc Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
TWI450896B (zh) 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
JP6854752B2 (ja) 2014-07-30 2021-04-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｈｄｌ上昇剤又はｈｄｌ模倣剤を用いた治療に対する応答性を予測するための遺伝マーカー

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
WO1998033775A1 (en) * 1997-02-03 1998-08-06 American Home Products Corporation 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
AU1048801A (en) 2001-06-12
HUP0203521A2 (hu) 2003-02-28
KR20020058057A (ko) 2002-07-12
PE20010904A1 (es) 2001-09-10
BG106854A (bg) 2002-12-29
CO5271716A1 (es) 2003-04-30
EE200200277A (et) 2003-10-15
NO20022558D0 (no) 2002-05-29
MA26845A1 (fr) 2004-12-20
ECSP003792A (es) 2002-04-23
PL355892A1 (en) 2004-05-31
IS6338A (is) 2002-04-12
MXPA02005354A (es) 2002-12-11
GT200000199A (es) 2002-05-23
TNSN00231A1 (fr) 2002-05-30
WO2001040190A1 (en) 2001-06-07
AP2002002531A0 (en) 2002-06-30
UY26454A1 (es) 2001-07-31
CN1402711A (zh) 2003-03-12
PA8506301A1 (es) 2002-08-26
TR200201446T2 (tr) 2002-11-21
OA12099A (en) 2006-05-04
IL149097A0 (en) 2002-11-10
BR0015836A (pt) 2002-08-06
JP2003515592A (ja) 2003-05-07
CA2392979A1 (en) 2001-06-07
EP1246804A1 (en) 2002-10-09
EA200200510A1 (ru) 2002-10-31

Similar Documents

Publication Publication Date Title
NO20022558L (no) 4-karboksyamino-2-etyl-1,2,3,4-tetrahydrokinolinkrystall som CETP inhibitor
NO996108L (no) 9-oksinerytromycinderivater
ATE255589T1 (de) Kristallin form i von clarithromycin
SE9904738D0 (sv) Novel compounds
CA2296604A1 (en) Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
NO20025821L (no) 2-aminokarbonyl-9H-purinderivater
YU49312B (sh) Kristalni hidratni derivati 3,4,4-trisupstituisanih - peperidinil-n-alkilkarboksilata, njihovi intermedijari i postupak za dobijanje
NO2005025I1 (no) Krystalinsk ceftiofurfri syre, fremgangsmate for fremstilling av denne, og farmasoytisk preparat
NO20051695L (no) Nye spirokondenserte kinazolinoner og deres anvendelse som fosfodiestereaseinbibitorer
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
FI113644B (fi) Menetelmä terapeuttisesti aktiivisten N-substituoitujen 3- atsabisykloalkaanijohdannaisten valmistamiseksi
TR199901578T2 (xx) Klaritromisin form 0 kristali
NO20020925L (no) N-heterosykliske derivater av NOS-inhibitorer
DK0696281T3 (da) Hidtil ukendte 5-pyrrolyl-2-pyridylmethylsulfinylbenzimidazolderivater
NO20015172L (no) 1-metyl-erytromycin-derivater
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
NO20065784L (no) Steroidforbindelser og anvendelse av slike
NZ236293A (en) 1-(alkyl or alkoxyalkyl)-4-phenyl piperidine-4-carboxylic acid amide derivatives; preparatory processes and pharmaceutical compositions
NO971625L (no) Nye peptider med immunomodulatoriske effekter
FI934298A0 (fi) Kristallin tiagabine-hydrokloridmonohydrat, dess framstaellning och dess anvaendning
WO2000059285A3 (en) NOVEL LACTAM INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE
NO20000722L (no) 2-(4-aryl eller heteroaryl-piperazin-1-ylmetyl)-1H- indolderivater
NO934196L (no) N,N-disubstituerte arylcykloalkylaminer, deres salter, legemidler inneholdende disse forbindelser, deres anvendelse og fremgangsmåte for deres fremstilling
BG104447A (en) Biphenylamidine derivatives
EA200000389A3 (ru) Новые замещенные пиридины или пиперидины, способ их получения и содержащие их фармацевтические композиции

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application